MK3475-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158).

Print this page

MK3475-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158).

Objective 1: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarkerunselected subjects with any one of multiple types of advanced (metastatic and/or unresectable) solid tumors (Groups AJ)

Objective 2: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarkerselected subjects with any one of multiple types of advanced (metastatic and/or unresectable) solid tumors (Groups AK). The primary biomarkers to be evaluated are (1) tumor expression of PDL1 by IHC (Groups AJ),(2) tumor GEP by RNA analysis (Groups AJ), and (3) tumor MSIH (Groups AK).

Protocol Number: 051516
Phase: Phase II
Applicable Disease Sites: Any Site
Drugs Involved: Pembrolizumab (MK-3475)
Principal Investigator: Janice Mehnert
Research Nurse: Yasmeen Beckett
Scope: National
Therapies Involved: Immunotherapy
Participating Institutions: Rutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health